A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

  1. Kuemmel, S.
  2. Campone, M.
  3. Loirat, D.
  4. Lopez, R.L.
  5. Thaddeus Beck, J.
  6. de Laurentiis, M.
  7. Im, S.-A.
  8. Kim, S.-B.
  9. Kwong, A.
  10. Steger, G.G.
  11. Adelantado, E.Z.
  12. Duhoux, F.P.
  13. Greil, R.
  14. Kuter, I.
  15. Lu, Y.-S.
  16. Tibau, A.
  17. Özgüroğlu, M.
  18. Scholz, C.W.
  19. Singer, C.F.
  20. Vega, E.
  21. Wimberger, P.
  22. Zamagni, C.
  23. Couillebault, X.-M.
  24. Fan, L.
  25. Guerreiro, N.
  26. Mataraza, J.
  27. Sand-Dejmek, J.
  28. Chan, A.
  29. Show all authors +
Journal:
Clinical Cancer Research

ISSN: 1557-3265 1078-0432

Year of publication: 2022

Volume: 28

Issue: 1

Pages: 106-115

Type: Article

DOI: 10.1158/1078-0432.CCR-20-3955 GOOGLE SCHOLAR

Sustainable development goals